ABL1 and Ewing sarcoma: However, in a phase II trial of imatinib mesylate, which inhibits c-KIT, platelet derived growth factor receptors and BCR-ABL, only 1/24 ES patients responded [45] and in a second study of 13 ES patients no responses were observed [43].